Key Points
- Cristian Luput bought a total of 48,145 shares of MAIA across Nov 25–28 (10,000 at $0.98, 20,000 at $1.08, 18,145 at $1.11), spending about $51,540.95; his latest purchase raised his direct holdings to 437,628 shares, a ~4.33% increase.
- MAIA is a clinical‑stage biotech whose lead candidate THIO is in Phase II for non‑small cell lung cancer; the company reported quarterly EPS of ($0.27) vs. consensus ($0.19) and analysts forecast roughly -1.3 EPS for the year.
- The stock has a market cap of about $44.44 million, opened at $1.20 (1‑year range $0.87–$2.74), and institutional ownership is low at 5.65%.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Cristian Luput acquired 18,145 shares of the company's stock in a transaction on Friday, November 28th. The stock was acquired at an average price of $1.11 per share, with a total value of $20,140.95. Following the purchase, the director directly owned 437,628 shares in the company, valued at approximately $485,767.08. This represents a 4.33% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Cristian Luput also recently made the following trade(s):
- On Wednesday, November 26th, Cristian Luput bought 20,000 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.08 per share, for a total transaction of $21,600.00.
- On Tuesday, November 25th, Cristian Luput bought 10,000 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $0.98 per share, for a total transaction of $9,800.00.
MAIA Biotechnology Trading Up 1.7%
NYSEAMERICAN MAIA opened at $1.20 on Tuesday. The company has a market cap of $44.44 million and a price-to-earnings ratio of -1.64. MAIA Biotechnology, Inc. has a 1-year low of $0.87 and a 1-year high of $2.74. The company has a 50 day moving average of $1.32 and a 200-day moving average of $1.56.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.08). On average, equities research analysts forecast that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.
Institutional Investors Weigh In On MAIA Biotechnology
A number of large investors have recently bought and sold shares of the company. Centerpoint Advisory Group bought a new position in MAIA Biotechnology in the 2nd quarter valued at about $28,000. Geode Capital Management LLC boosted its position in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock worth $400,000 after acquiring an additional 7,746 shares in the last quarter. Centric Wealth Management increased its stake in MAIA Biotechnology by 740.2% in the second quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after acquiring an additional 505,150 shares during the last quarter. Marshall Wace LLP acquired a new position in MAIA Biotechnology during the second quarter valued at approximately $29,000. Finally, Jane Street Group LLC bought a new stake in MAIA Biotechnology during the second quarter worth $52,000. 5.65% of the stock is currently owned by institutional investors and hedge funds.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
